Dose 1 for Diabetic Macular Edema
This trial tests a potential drug to help people with vision problems caused by diabetes or macular degeneration. It will assess its safety and effectiveness.
- Diabetic Macular Edema
- Age-related Macular Degeneration (AMD)
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
How many individuals are partaking in this research endeavor?
"This research requires 92 qualified individuals to participate. Recruitment extends across Lemont, Illinois and Reno, Nevada with sites located in those respective cities."
Are there any openings for participants in this trial?
"The trial's profile on clinicaltrials.gov affirms that enrolment is still open; the study was initially posted June 12th 2023 and its most recent update occurred two days later, on June 14th of the same year."
How far-reaching is the availability of this trial?
"This study is currently recruiting patients at 5 distinct sites, such as Lemont in Nevada and Reno in Nevada. Additionally, Germantown located in Tennessee serves as another recruitment centre, with a further five locations also participating."